Chiba

我们是谁

  • 1 月 17, 2024
    Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
  • 1 月 10, 2024
    Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
  • 1 月 9, 2024
    A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) ( CheckMate 8HW )
  • 7 月 26, 2022
    一项针对转移性结直肠癌晚期患者的 Nivolumab-relatlimab 固定剂量联合疗法对比瑞戈非尼或 TAS-102 的研究
  • 5 月 23, 2022
    索托拉西布和帕尼单抗与研究者选择治疗克氏鼠肉瘤(KRAS)p.G12C 突变患者(代码 300)
  • 4 月 5, 2022
    Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
  • 4 月 5, 2022
    Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
  • 4 月 5, 2022
    一项针对晚期实体瘤患者的BMS-986340单药及与Nivolumab联合用药研究
  • 4 月 5, 2022
    A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
  • 4 月 5, 2022
    A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER)